Safety Profile
Known Safety Concerns
- Avoid in severe immunocompromise
- Temporary bloating and gas as microbiome adjusts
- Check viability (CFU count) at expiration
- Generally very safe for healthy adults
Contraindications
- Avoid in severe immunocompromise
- Temporary bloating and gas as microbiome adjusts
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Lactobacillus paracasei is a well-studied probiotic strain with evidence for immune modulation and respiratory tract infection prevention. Generally safe for healthy adults. Caution in severely immunocompromised individuals as with all live bacterial supplements.
Biological and Chemical Classification
- Scientific Name
- Lactobacillus paracasei (Lacticaseibacillus paracasei)
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Probiotic
- Evidence consistency: High consistency across studies (100%)
- Avoid in severe immunocompromise
- Temporary bloating and gas as microbiome adjusts
- Check viability (CFU count) at expiration
- Generally very safe for healthy adults
The available scientific evidence for Lactobacillus Paracasei indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 25 მარ 2026, 12:57
Evidence Distribution
-
Observational / other LOW evidence YELLOWThe Uric Acid Degrading Probiotics MC1 in Quercetin Nanocoatings and Bioactive Polysaccharides Microgels for Anti-Hyperuricemia and Gut Microenvironment Modulation. ↗Li Z et al.. The Uric Acid Degrading Probiotics MC1 in Quercetin Nanocoatings and Bioactive Polysaccharides Microgels for Anti-Hyperuricemia and Gut Microenvironment Modulation.. Adv Healthc Mater. 2026. PMID:41870112.PMID 41870112 ↗Journal Adv Healthc MaterYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41870112/
-
Observational / other LOW evidence YELLOWCombination of Tripterygium glycosides and Lactobacillus paracasei sensitises epithelial ovarian cancer to cisplatin via downregulating Keap1-Nrf2-GPX4 signalling pathway. ↗Tian M et al.. Combination of Tripterygium glycosides and Lactobacillus paracasei sensitises epithelial ovarian cancer to cisplatin via downregulating Keap1-Nrf2-GPX4 signalling pathway.. Cell Mol Biol Lett. 2026. PMID:41862794.PMID 41862794 ↗Journal Cell Mol Biol LettYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41862794/
-
Observational / other LOW evidence YELLOWImprovement of starch fine structure, physicochemical properties and digestive characteristics of adlay seeds by fermentation with Lactobacillus plantarum and Lactobacillus paracasei. ↗Xu S et al.. Improvement of starch fine structure, physicochemical properties and digestive characteristics of adlay seeds by fermentation with Lactobacillus plantarum and Lactobacillus paracasei.. Int J Biol Macromol. 2026. PMID:41861878.PMID 41861878 ↗Journal Int J Biol MacromolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41861878/
-
Observational / other LOW evidence YELLOWEfficacy of a probiotic-prebiotic mix on chronic constipation symptoms in the elderly: results of a pilot study. ↗Montarsolo P et al.. Efficacy of a probiotic-prebiotic mix on chronic constipation symptoms in the elderly: results of a pilot study.. Minerva Gastroenterol (Torino). 2026. PMID:41823986.PMID 41823986 ↗Journal Minerva Gastroenterol (Torino)Year 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41823986/
-
Observational / other LOW evidence YELLOWEfficient utilization of compound oligosaccharides by Lactobacillus paracasei ProSci-92 and their application in fermented milk. ↗Gao S et al.. Efficient utilization of compound oligosaccharides by Lactobacillus paracasei ProSci-92 and their application in fermented milk.. J Dairy Sci. 2026. PMID:41780873.PMID 41780873 ↗Journal J Dairy SciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41780873/
-
Observational / other LOW evidence YELLOWLactobacillus paracasei LP18 ameliorated inflammation and intestinal barrier dysfunction in severe acute pancreatitis via gut microbiota-mediated regulation of butyrate metabolism. ↗Cao J et al.. Lactobacillus paracasei LP18 ameliorated inflammation and intestinal barrier dysfunction in severe acute pancreatitis via gut microbiota-mediated regulation of butyrate metabolism.. Front Microbiol. 2026. PMID:41767557.PMID 41767557 ↗Journal Front MicrobiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41767557/
-
Observational / other LOW evidence YELLOWSpecies synergy effects on milky aroma are conditioned by moisture-gradient driven pore evolution of protein-fat networks in fermented sausages. ↗Song F et al.. Species synergy effects on milky aroma are conditioned by moisture-gradient driven pore evolution of protein-fat networks in fermented sausages.. Meat Sci. 2026. PMID:41762609.PMID 41762609 ↗Journal Meat SciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41762609/
-
Observational / other LOW evidence YELLOWEvaluation of clinical responses to probiotics and colchicine in PFAPA patients based on autoinflammatory diseases activity index (AIDAI) scores. ↗Yabanci Erten ES et al.. Evaluation of clinical responses to probiotics and colchicine in PFAPA patients based on autoinflammatory diseases activity index (AIDAI) scores.. Pediatr Res. 2026. PMID:41723264.PMID 41723264 ↗Journal Pediatr ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41723264/
-
Observational / other LOW evidence YELLOWEvaluation and predictive modelling of okara (poly)phenol metabolite production via lactic acid fermentation. ↗Agullu00f3 V et al.. Evaluation and predictive modelling of okara (poly)phenol metabolite production via lactic acid fermentation.. Food Microbiol. 2026. PMID:41722992.PMID 41722992 ↗Journal Food MicrobiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41722992/
-
Observational / other LOW evidence YELLOWProbiotic supplementation and dental caries prevention in children and adolescents: a systematic review of strain-specific and context-dependent effects. ↗Rodriguez G et al.. Probiotic supplementation and dental caries prevention in children and adolescents: a systematic review of strain-specific and context-dependent effects.. Clin Oral Investig. 2026. PMID:41706206.PMID 41706206 ↗Journal Clin Oral InvestigYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41706206/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Lactobacillus Paracasei. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Lactobacillus Paracasei
A score of 2.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.